S. Kuriyakose

发表

Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study

Martina Kovac, Lusiné Kostanyan, N. Mesaros, 2018, Human vaccines & immunotherapeutics.

Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial.

O. Vanderkooi, G. Zuccotti, F. Martinón-Torres, 2019, Vaccine.

Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine.

S. Kuriyakose, S. Houard, C. Tielemans, 2010, Kidney international.

Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study

S. Kuriyakose, N. Meyer, Winnie Janssens, 2020, Human vaccines & immunotherapeutics.

Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants.

S. Kuriyakose, O. Van Der Meeren, D. Scheifele, 2015, Vaccine.

mmunogenicity and safety of 3-dose primary vaccination with ombined DTPa-HBV-IPV / Hib vaccine in Canadian Aboriginal and on-Aboriginal infants avid

S. Kuriyakose, W. Scheifelea, Murdo Fergusonc, 2015 .

Immunogenicity of Infanrix™ hexa administered at 3, 5 and 11 months of age.

S. Kuriyakose, O. Van Der Meeren, Devayani Kolhe, 2012, Vaccine.

The safety and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) booster vaccine in healthy Vietnamese children.

S. Kuriyakose, D. Anh, H. Han, 2016, Vaccine.

Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine

G. Icardi, S. Esposito, S. Kuriyakose, 2012, Human vaccines & immunotherapeutics.

Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium.

P. van Damme, H. Theeten, S. Kuriyakose, 2015, Vaccine.

Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults

S. Kuriyakose, S. Houard, J. Beran, 2010, Human vaccines.

Safety and Reactogenicity of the Inactivated Poliomyelitis

S. Kuriyakose, S. Shin, S. Ma, 2013 .

Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.

O. Vanderkooi, G. Zuccotti, F. Martinón-Torres, 2021, Vaccine.

Immunogenicity of the reduced-antigen-content dTpa vaccine (Boostrix(®)) in adults 55 years of age and over: a sub-analysis of four trials.

P. van Damme, S. Kuriyakose, P. McIntyre, 2011, Vaccine.

Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials.

M. Jadoul, G. Verpooten, S. Kuriyakose, 2011, Vaccine.

Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.

Lusiné Kostanyan, N. Mesaros, S. Kuriyakose, 2018, Vaccine.

Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region

G. Leroux-Roels, A. Theamboonlers, Y. Poovorawan, 2011, Journal of viral hepatitis.

Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents.

S. Kuriyakose, J. Jacquet, J. Beran, 2010, Vaccine.

Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years.

H. Marshall, S. Kuriyakose, E. Sokal, 2010, Vaccine.

Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age

S. Kuriyakose, S. Silfverdal, O. Van Der Meeren, 2014, Human vaccines & immunotherapeutics.

Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study

P. van Damme, R. Booy, S. Kuriyakose, 2010, BMC infectious diseases.

A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in th

S. Faust, A. Pollard, A. Finn, 2018, Vaccine.

Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.

S. Kuriyakose, S. Roy-Ghanta, O. Van Der Meeren, 2016, Vaccine.

Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial.

O. Vanderkooi, G. Zuccotti, F. Martinón-Torres, 2019, Vaccine.

An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.

S. Kuriyakose, N. Klein, L. Friedland, 2012, Vaccine.